89bio, Inc. (ETNB)
$14.84+0.00%Close
BUYBULL · day 31
Key stats
- Market cap
- $2.2B
- Beta
- 1.26
- P/E (TTM)
- -4.23
- 1W
- +0.27%
- vs SPY 1W
- +0.41%
Industry peers
FMP comparable companies · ranked by market cap
- IBRXBUYImmunityBio, Inc.$10.6BRECOVERYQ 8$10.12-3.16%
- COGTSELLCogent Biosciences, Inc.$5.1BCRISISQ 12$29.78-5.67%
- RCUSSELLArcus Biosciences, Inc.$3.1BCRISISQ 17$24.34-7.52%
- DNLISELLDenali Therapeutics Inc.$3.0BCRISISQ 8$18.95-2.90%
- BEAMBUYBeam Therapeutics Inc.$2.6BRECOVERYQ 13$25.13-2.79%
- LQDASELLLiquidia Corporation$2.5BCRISISQ 12$27.67-3.11%
- RXRXBUYRecursion Pharmaceuticals, Inc.$2.1BCRISISQ 0$4.01-4.24%
- GLPGGalapagos N.V.$1.8B$27.98
- AGIOSELLAgios Pharmaceuticals, Inc.$1.8BRECOVERYQ 4$30.82-1.98%
- OCULSELLOcular Therapeutix, Inc.$1.7BCRISISQ 3$7.56-4.23%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ETNB?
- LOPJLB’s latest quantitative signal on 89bio, Inc. (ETNB) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ETNB in?
- 89bio, Inc. (ETNB) is currently classified in the BULL HMM market regime on LOPJLB.
- What does 89bio, Inc. (ETNB) do?
- Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has p…